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CASE REPORT
Feminizing Genitoplasty in a young girl with Glanzmann’s thrombastheniamanagement of haemostasis
Kashaf Khalid Turk,1 Zafar Nazir2

Abstract
We report peri- and post-operative management of
haemostasis in a 11-year old girl with Glanzmann
Thrombasthenia (GT) who had feminizing genitoplasty for
genital ambiguity due to Congenital Adrenal Hyperplasia
(CAH-21 Hydroxylase deficiency). A blend of Glanzmann
Thrombasthenia (GT) and DSD 46XX due to CAH is not
reported in literature. Surgery particularly genitourinary
reconstruction in patients with GT is challenging due to
risk of intra and post-operative bleeding. Haemostasis can
successfully be achieved with platelet transfusions,
antifibrinolytic (Tranexamic acid) and judicious use of
recombinant factor VIIa (rFVIIa) even in a resource limited
setting.
Keywords: Inherited Platelet disorders, Feminizing
Genitoplasty, Disorders of Sexual Differentiation (DSD),
Urogenital Sinus, Glanzmann's Thrombasthenia,
Recombinant Factor VIIa (rFVIIa).
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Introduction
Glanzmann's Thrombasthenia (GT) is a rare autosomal
recessive disorder of platelet aggregation due to
qualitative/quantitative defect of platelet membrane
glycoproteins (IIb/IIIb). Reported incidence is 1: 1000,000
people worldwide.1,2 GT may be frequent in South-East Asia
where consanguinity is common.3 In a series of 211 patients
of Autosomal recessive inherited bleeding disorders
(ARBDs) from Pakistan, 9.6% patients had GT.4 Clinical
manifestation includes easy bruising, tendency to bleed
from muco-cutaneous surfaces e.g. epistaxis (bleeding from
the nose), menorrhagia( abnormally heavy bleeding at
menstruation), and bleeding after trauma or surgery.
In literature reports of children having GT undergoing
minor procedures (e.g. dental extraction, herniorrhaphy)
are common however, major surgical procedures
particularly the genitourinary reconstructions are
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sparingly reported.5-7 In this report we share the
experience of feminizing genitoplasty in a young girl with
DSD 46XX due to CAH (Congenital Adrenal Hyperplasia21 Hydroxylase deficiency), a rare autosomal recessive
disorder (Incidence, 1: 15,000) who also had GT. We
believe that blend of these two autosomal recessive
disorders is rare and is not reported in literature before.

Case Report
The patient was born to consanguineous parents. The
mother was known to have Glanzmann's Thrombasthenia
(GT) and delivered normally under the cover of platelet
transfusions. Examination in nursery revealed ambiguous
genitalia (enlarged clitoris, fused labio-scrotal folds and a
single perineal opening. After the investigations which
include serum electrolytes,17-hydroxyprogesteron,
Ultrasound Pelvis, karyotype and Genitogram, she was
diagnosed CAH-21-hydrooxylase deficiency and was
categorized as DSD 46 XX. Steroid replacement
(hydrocortisone and Florinef) was initiated. At 4.5 years she
was diagnosed GT; after an episode of intractable epistaxis.
Three further episodes of epistaxis were successfully
managed by platelet transfusions and local measures. She
was referred in June 2018 to Paediatric Surgery service at
the Aga Khan University Hospital, Karachi (AKUH.K),
Pakistan; at 11-years of age for feminizing genitoplasty.
Laboratory tests revealed Haemoglobin 12.5gm/dl,
Hematocrit 34%, WBC count 8 X 109/L, platelets 253 X
109/L, prothrombin time (PT) :11 seconds, and activated
partial thromboplastin time: 33 seconds. Bleeding time was
> 14 minutes and platelet aggregation with collagen,
adenosine diphosphate (ADP) and epinephrine was absent.
The patient was admitted electively for the reconstructive
surgery and co-managed with Paediatric Haematology
and Endocrinology. One hour prior to the procedure she
received stress dose (3 times the maintenance dose) of
hydrocortisone, 6 units of platelets concentrate and
tranexamic acid (10mg/kg).
The technical details of Feminizing genitoplasty (flap
Vaginoplasty, nerve-sparing clitoroplasty and labioplasty)
are reported in literature.8 Cystoscopy was the initial
procedure which revealed the length of the common
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urogenital sinus (UG) to be 3.0 cm. The procedure continued
for 3.15 hours. Excessive bleeding (>350 ml) was
encountered particularly during dissection of UG and
clitoroplasty. However, bleeding reduced (<50ml)
remarkably after a bolus of recombinant factor VIIa (rFVIIaNovo-sevenR), 90ug/kg. Additional dose of rFVIIa were
administered in recovery room and at time of dressing
change and removal of vaginal pack on 3rd postoperative
day. Tranexamic acid (10mg/kg) 3 times a day was
continued, and she received 6 units of platelets concentrate
twice daily for 7 days and once daily for the next 5 days. The
patient recovered well and was discharged from the hospital
on the 12th post-operative day. She did not experience any
adverse effects of rFVIIa treatment or further oozing from the
wound during hospitalization and on 8-week follow-up.

Discussion
Both GT and CAH are autosomal recessive inherited disorders
and caused by mutation of genes (TGA2B/ITGB3 and
CYP21A2) located on Chromosome 17 and 6 respectively.
Mechanism of presence of these rare disorders in one patient
is unknown and is not reported in literature. Perhaps it can be
explained by uniparental disomy (maternal or parental) i.e.
inheritance by offspring of two copies of a homologous
chromosome from one parent and none from the other.

as the cost of one dose of rFVIIa is US$ 560.00 in Pakistan
where per capita income is around US$ 5500. It was effective
in controlling intra and post-operative bleeding episodes.
The exact mechanism of rFVIIa as haemostatic agent is
not known. It is reported to bind activated platelets and
boost local thrombin generation and adhesion of GP
IIb/IIIa deficient platelets. As Fibrin is an active participant
in platelet aggregation; antifibrinolytics such as
tranexamic acid may have a role in management.2
In conclusion, surgical procedures particularly genitourinary
reconstructions in patients with GT can be carried out safely by
careful planning and coordination between haematologist
and the surgeon. rFVIIa is effective as an adjuvant to platelet
transfusions; in reducing bleeding. The reported approach
may also be applicable in children and adolescents with GT
having minor, major surgical and obstetric procedures.
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